Trial Profile
Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Sep 2021
Price :
$35
*
At a glance
- Drugs Zotiraciclib (Primary) ; Temozolomide
- Indications Anaplastic astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 30 Mar 2021 Results from phase 1 portion published in the Clinical Cancer Research
- 13 Jan 2021 Top-line results presented in an Adastra Pharmaceuticals media release.
- 27 Aug 2020 Status changed from recruiting to completed.